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Abstract The physiological function of a recently cloned splice
variant of insulin-like growth factor-I (IGF-I; mechano growth
factor (MGF)) was studied using an in vitro cell model. Unlike
mature IGF-I, the distinct E domain of MGF inhibits terminal
di¡erentiation whilst increasing myoblast proliferation. Blocking
the IGF-I receptor with a speci¢c antibody indicated that the
function of MGF E domain is mediated via a di¡erent receptor.
The results provide a basis for localized tissue adaptation and
helps explain why loss of muscle mass occurs in the elderly and
in dystrophic muscle in which MGF production is markedly
a¡ected. * 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Insulin-like growth factor-I (IGF-I) has been shown to be
involved in several cellular processes including tissue di¡er-
entiation [1], maintenance of tissue mass [2] and tissue repair
[3]. However, the IGF-I gene is spliced di¡erently in response
to di¡erent signals. Di¡erent peptides resulting from this al-
ternatively splicing have been reported to have di¡erent
modes of action [4].
Although the mature systemic type of IGF-I is a simple 70
amino acid peptide, its gene is unexpectedly large spanning a
region of over 90 kb of genomic DNA. Alternative splicing of
IGF-I gene results in di¡erent transcripts encoding several
IGF-I precursor proteins. Two of them produced by active
muscle in rodents are positive regulators of muscle hypertro-
phy [5,6]. One of these, IGF-I Ea, has been given various
names including muscle liver-type IGF-I [5] and muscle IGF
[7]. The other isoform, which is the IGF-I Eb in rodents,
corresponds to IGF-I Ec in human, and is only markedly
up-regulated in exercised and damaged muscle. Therefore it
has been named mechano growth factor (MGF) [4,6].
Although it has been known that IGF-I gene gives rise to
di¡erent peptides, the di¡erences in their physiological func-
tion have not been investigated.
Mammalian skeletal muscle di¡erentiation is a useful model
system for studying the molecular mechanisms that switch the
cellular program from proliferation to di¡erentiation. The
murine C2C12 cell line is a pure, immortalized mouse skeletal
muscle cell line, the cells of which are morphologically similar
to primary myoblasts [8^10] and can be grown without con-
tamination from other cell types. When grown to cellular
con£uence and deprived of certain growth factors, C2C12
myocytes enter the terminal di¡erentiation pathway and begin
to fuse to form myotubes and express muscle-speci¢c proteins.
This di¡erentiation process is apparently regulated by several
growth factors including IGF-I. However, IGF-I is unique in
that it stimulates both proliferation and di¡erentiation of skel-
etal muscle cells in culture [11].
The aim of this study is to use murine C2C12 skeletal
muscle cell line to investigate potential physiological function
of IGF-I Ea and MGF as well as their interactions by deter-
mining the mitotic index and creatine kinase (CK) expression
as a marker of terminal di¡erentiation [12,13].
2. Materials and methods
2.1. Cell culture and transfection
Proliferating C2C12 mouse myoblasts were maintained and pas-
saged as subcon£uent monolayers in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% fetal bovine serum, plus 0.5% ampicillin
and gentamicin (GM) at 37‡C, with 5% CO2. MGF and IGF-I Ea
cDNAs [4] were inserted in frame with the N-terminal His tag and the
enterokinase site downstream of the human cytomegalovirus pro-
moter of the pcDNA 3.1/His vector (Invitrogen). Following digestion
with Nrol (208 bp) and Bstll071 (3319) the backbone of the
pcDNA3.1/His Vector containing the ampicillin resistance and the
Co1EI site was removed. The remaining sequence containing the
MGF or L.IGF-1 cassette was used in stable transfection of C2C12
mouse muscle myoblast cell line (European Collection of Cell Cul-
tures) with Superfect Transfection Reagent (Qiagen). The stable ex-
pression of MGF or IGF-I Ea clones was grown in a selective medium
containing neomycin (G418) for 4 weeks.
2.2. Reverse transcription-polymerase chain reaction (RT-PCR)
In order to test which C2C12 cell clones positively expressed MGF
or IGF-I Ea, the total cellular RNA was prepared from cells trans-
fected with MGF, IGF-I Ea and non-transfected C2C12 cells using a
total RNA isolation kit (Promega). The sequences of the primers used
were: forward primer is 5P-TAAGGTACCCGGACCGGAGACGC-
TCTGCGGTGCT-3P ; and reverse primer is 5P-TCAGTCTAGAA-
TGTTTACTTGTGTATTTCATTGG-3P. As both of the primers in-
cluded part of the vector and part of the insert, only the mRNA of the
introduced gene was ampli¢ed and not the endogenous MGF and
IGF-I Ea cDNA in the transfected C2C12 cells. Using these primers
a RT-PCR was performed.
2.3. MGF peptide synthesis
A predicted peptide resulting from the IGF-I Ec [14] was synthe-
sized by Applied Biosystems (Eurogentec, Belgium) using standard
solid-phase methodology and puri¢ed to s 95% by HPLC. Validation
of synthetic peptide was accomplished by total amino acid composi-
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tion and HPLC. The sequence of the synthetic peptide was NH2-Try-
Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-
Gly-Ser-Thr-Phe-Glu-Glu-His-Lys-COOH.
2.4. Analysis of CK activity
Cells were passaged and maintained in 12-well plates in GM me-
dium until 70% con£uent (3 days). They were then induced to di¡er-
entiate in Dulbecco’s modi¢ed Eagle’s medium supplemented with 2%
horse serum, plus 0.5% ampicillin and gentamicin (DM). At the in-
dicated times, cells in DM medium were washed three times with PBS,
lysed by incubating with reporter lysis bu¡er (Promega) for 15 min at
room temperature, and harvested by scraping. The concentration of
total protein was determined by BCA protein assay (Sigma). CK
activity was determined using the creatine phosphokinase assay kit
(Sigma Diagnostics). Brie£y, 0.1 ml of cell lysate was reacted with
phosphocreatine and ADP^glutathione for 30 min at 37‡C. The re-
action was stopped by adding p-hydroxymercuribenzoate and the col-
or reaction was induced by addition of K-naphthol and 0.05% diace-
tyl. Spectrophotometric reading was taken at 520 nM, and CK units
were determined from a calibration curve generated by creatine stan-
dards. All data points represent the means of triplicate determinations
from two repeated independent experiments.
2.5. Cell proliferation assay
In order to determinate the extent of cellular proliferation, the in-
corporation of 5-bromo-2P-deoxyuridine (BrdU) was quanti¢ed using
BrdU labelling and detection kit (Roche) as previously described [15].
Brie£y, 5000 cells were cultured with GM in 96-well microtiter plates
at 37‡C under 5% CO2. At indicated times after plating, 10 WM BrdU
was added into each well. The cells were continuously cultured under
the same conditions for 2 h; during which time BrdU was incorpo-
rated into freshly synthesized DNA. Following ¢xation of cells, cel-
lular DNA was partially digested by nuclease treatment. The incorpo-
rated BrdU was detected and quanti¢ed by the peroxidase-labelled
antibody to BrdU. The peroxidase catalyzes the cleavage of the sub-
strate which produces a color reaction. The absorbance at V 405 nm is
directly correlated to the level of BrdU incorporated into cellular
DNA was measured using a microplate reader (Bio-Rad) and indi-
cated the extent of myoblasts proliferation. All data points represent
the means of eight measurements from four repeated experiments on
each cell clone.
2.6. Investigation of proliferation mechanism of MGF action on
C2C12 cells
Normal C2C12 cells were plated (each well containing 5000 cells) in
96-well microtiter plates and maintained in GM for 3 days. Cells were
then placed in serum-free medium for 12 h before they were exposed
to di¡erent concentrations of MGF peptide in serum-free Dulbecco’s
modi¢ed Eagle’s medium containing 100 Wg/ml of BSA for 24 h. For
the purpose of comparison, a mature human IGF-I peptide (Pharma-
cia) was included in the experiments. In order to investigate pathway
though which the MGF act on in C2C12 myoblast, a speci¢c anti-
IGF-I receptor (Ab-1) antibody (Oncogene) was included in medium
at the same time when cells were exposed to di¡erent concentration of
MGF or IGF-I peptide. The concentration of the antibody (1000 ng/
ml) was used according to the manufacturer’s recommendation. All
the measurement was repeated four times using di¡erent plates and
eight wells were used for each concentration of the growth factor.
2.7. Statistical analysis
ANOVA was used to analysis the signi¢cance of the di¡erences in
the means for CK activity, and the rate of incorporation of BrdU in
transfected clones and treated cells. In the ¢gures the mean values are
expressed as meansQS.E.M.
3. Results
3.1. MGF inhibits terminal di¡erentiation of C2C12 cells
Two of MGF-positive C2C12 clones and two IGF-I Ea
clones were used to study the e¡ects of MGF and systemic
IGF-I Ea on myoblast proliferation and di¡erentiation. Fig. 1
demonstrates that positive MGF and IGF-I Ea C2C12 clones
expressed transfected MGF or IGF-I Ea mRNA, whilst no
exogenous MGF mRNA was detected in control C2C12 cells.
When cells were induced to undergo myogenesis in the di¡er-
entiation medium (DM), it was found that positive terminal
di¡erentiation was prevented in MGF-positive cells. Even
these cells kept in DM for 14 days, remained as myoblasts
(Fig. 2A). In contrast, those of the IGF-I Ea-positive clone
formed myotubes (Fig. 2B). The normal C2C12 cells showed
less cellular proliferation as well as forming myotubes (Fig.
2C).
In order to further test that the inhibition of cell di¡eren-
tiation was due to the e¡ects of MGF, normal C2C12 cells
were treated with either synthetic MGF peptide or the me-
dium harvested from MGF-transfected cells. Fig. 2 shows that
both synthetic (D) and MGF condition medium (E) inhibited
cell di¡erentiation. It is interesting to note that this inhibition
was reversed when the synthetic MGF peptide (G) or MGF
conditional medium (H) was withdrawn and the cells started
fusing and forming myotubes in a similar way to untreated
C2C12 cells (F).
Fig. 3 shows that the induction of CK activity was inhibited
(P6 0.001) in MGF-positive cell clones and that similar re-
sults were obtained when normal C2C12 cells were treated
with MGF peptide.
3.2. MGF increases C2C12 cell proliferation
Cellular proliferation of MGF-positive clones was analyzed
using BrdU incorporation assay. The incorporated BrdU was
measured at 12, 24, 36 and 48 h after plating. There was a
signi¢cant increase in BrdU uptake in MGF cells at 24, 36
and 48 h after plating comparing to the non-transfected
C2C12 cells (Fig. 4). IGF-I Ea also increased BrdU uptake
into new synthetic DNA comparing to normal cell after 24 h
of plating but it is not quite as e¡ective as MGF in stimulat-
ing cell proliferation.
3.3. MGF increases cell proliferation but not via the
IGF-I receptor
Fig. 5 shows that MGF stimulated normal C2C12 cells
proliferation in a dose-dependent manner (A). Interestingly,
this stimulation was not inhibited by blocking IGF-I receptors
Fig. 1. Detection of the introduced MGF or IGF-I Ea mRNA in
MGF- or IGF-I Ea-transfected cell clones. The results showed that
in the MGF-positive cells (lane 2) transfected MGF mRNA and in
IGF-I Ea-positive cells (lane 3) transfected IGF-I Ea mRNA was
detected using the speci¢c primers. These primers did not detect any
endogenous MGF or IGF-I Ea mRNA in control C2C12 cells as
shown in lane 4. Lane 1 is a 1 kb DNA ladder; lane 5 is a non-
cDNA negative control.
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(B) using an anti-IGF-I receptor (Ab-1) antibody (Oncogene)
which has been used previously in similar studies. On the
other hand, IGF-I also increased normal cells proliferation
(Fig. 6A). This stimulation was blocked by the IGF-I receptor
antibody (Fig. 6B). The results strongly suggest that MGF
inducing C2C12 myoblast proliferation was not via the type
1 IGF-I receptor and involves a di¡erent signalling pathway.
4. Discussion
Several growth factors are initially synthesized as pro-pep-
tide precursors that are post-translationally processed to pro-
Fig. 2. Cell pro¢le of MGF-positive (A), IGF-I Ea-positive (B) and normal control C2C12 (C) cells grown in di¡erentiation media for 14 days.
This demonstrates that MGF-positive cells stayed as mononuclear cells whilst almost all normal control C2C12 cells had by 14 days fused to
form multinuclear myotubes. In the IGF-I Ea-positive clone, most cells had already fused and formed myotubes, but some were still in the
myoblast state. To con¢rm the inhibition of myoblast di¡erentiation by MGF, normal C2C12 cells were treated with either synthetic MGF
peptide or the medium harvested from MGF-transfected cells (ratio 1:1). When MGF peptide (100 ng/ml) was added to the di¡erentiation me-
dium (D) or the medium from the MGF-transfected clone was added in a 1:1 ratio (E), the normal C2C12 cells lost their capability to form
myotubes. When the MGF peptide (G) or MGF-transfected conditional medium (H) were withdrawn from the above di¡erentiation medium
after 24 h, the cells again began to fuse and formed myotubes in a similar way to untreated C2C12 cells (F).
Fig. 3. Muscle CK (MCK) activity in normal C2C12 cells, IGF-I
Ea- and MGF-positive cells and normal C2C12 cells plus the MGF
peptide (100 ng/ml) for up to 6 days incubation in di¡erentiation
medium (DM). All data points represent the means of enzymatic ac-
tivity determinations carried out in triplicate from two duplicate ex-
periments. Values shown are the meanQS.E.M. for n=6. The lack
of MCK as a marker of terminal di¡erentiation was very signi¢cant
in MGF-transfected cells and those treated with MGF peptide (AN-
OVA P6 0.001 when comparing MGF clone and MGF treated cells
with control IGF-I Ea clone and control C2C12 cells).
Fig. 4. The comparison of the number of cells in a proliferative
state (determined by incorporation of BrdU shown as absorption at
405nm) within MGF-transfected, IGF-I Ea-transfected and control
C2C12 cells at 12, 24, 36 and 48 h after plating. The results showed
that after 24 up to 48 h of plating MGF-transfected cells exhibited
signi¢cantly higher proliferation compared to normal control C2C12
cells (P6 0.001). Although the rate of proliferation in IGF-I Ea-
transfected cells is about twice time as high as the control cells
(P6 0.01), it is not as high as in MGF-transfected cells. Values
shown are the meanQS.E.M.
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duce multi-peptides with distinct biological activities. Exam-
ples include pro-insulin [16], pro-EGF [17], pro-TGF (trans-
forming growth factor) [18] and pro-glucagon [19]. Because of
alternative splicing of 3P-exons, there are di¡erent pro-IGF-I
precursors within human tissue including IGF-I Ea [20], IGF-
I Eb [21] and IGF-I Ec [14]. It has been suggested that the E
peptides of these pro-IGF-I precursors may function as inde-
pendent growth factors [22]. However, the physiological func-
tions of the E domain had not been studied. This study dem-
onstrated that E peptide of the splice variant, MGF [4,6], is
biologically active and has a distinct activity compared to that
of mature IGF-I in that it can increase myoblasts proliferation
but it totally inhibits the myotubes formation. Also the selec-
tive blocking of the IGF-I receptor provides evidence that
MGF increases myoblast proliferation via a di¡erent signal-
ling pathway.
The growth and regeneration of postnatal and adult skeletal
muscle involves mononucleated cells called satellite cells or
residual myoblast. In the quiescent state they reside between
the basement membrane and plasma membrane of myo¢bers.
They are activated in response to diverse stimuli, including
stretching, exercise, injury, and electrical stimulation [23]. Sat-
ellite cell activation as measured by speci¢c marker appear to
change in association with MGF level of expression [24]. Sev-
eral growth factors such as ¢broblast growth factor, TGF-L
and IGF have been implicated to the proliferation, fusion and
di¡erentiation of skeletal muscle satellite cell [25]. MGF, one
isoform of IGF-I, was shown in this study to stimulate myo-
blasts proliferation but depress di¡erentiation which appears
to play a role in this process, particularly as MGF is expressed
before IGF-I following muscle damage as the increase in ac-
tive in that nuclei is a pre-request for local tissue repair and
adaptation. Although the myoblasts used in this study are
from a cell line it is most likely that they respond in the
same manner to MGF and IGF-I Ea as the residual myo-
blasts in adult muscle in vivo.
Skeletal muscle regenerative capacity has been shown to
decline with age [26,27]. As the satellite cell population within
skeletal muscle was not signi¢cantly lower in the older com-
paring to young men and women [28]. This incapacity to
Fig. 5. Cell proliferation data in response to MGF treatment after
blocking the IGF-I receptor. Shown in (A) is the dose-independent
response of normal C2C12 cell proliferation (indicated by the absor-
bance of incorporated BrdU) to di¡erent concentrations of MGF
peptide in serum-free medium (A). Maximum cell proliferation was
obtained when the concentration of MGF reached to 5 ng/ml,
which was signi¢cant between treated and control cells (P6 0.001).
When anti-IGF-I receptor antibody was included in the medium
(B), this dose-independent response was not a¡ected, indicating that
the increasing myoblast proliferation function of MGF was not via
the IGF-I receptor. Values shown are the meanQS.E.M.
Fig. 6. The data for IGF-I treatment on cell proliferation after
blocking the IGF-I receptor. Shown in (A) is the dose-independent
response of normal C2C12 cell proliferation (indicated by the absor-
bance of incorporated BrdU) to di¡erent concentrations of mature
IGF-I in serum-free medium. When a neutralization anti-IGF-I anti-
body was included in the medium (B), this dose-independent re-
sponse disappeared indicating that the myoblast proliferation func-
tion of mature IGF-I is indeed via IGF-I receptor. Values shown
are the meanQS.E.M.
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regenerate in aged muscle seems to be due to decreased pro-
liferation ability of satellite cells [29]. Considerably lower ex-
pression of the local MGF in older muscles in response to
mechanical overload has been associated with the failure to
activate satellite cells [24]. The capacity of MGF increasing
myoblast proliferation shown in this study helps to explain the
muscle loss that occurs during ageing.
In contrast to normal muscle, the mRNA for MGF is not
detectable in dystrophic muscles even when subjected to
stretch and/or electrical stimulation [30]. Decreased numbers
of proliferative cells were found in dystrophic muscle follow-
ing muscle damage [31]. This indicated that in dystrophic
muscles myogenic satellite cells cannot undergo self-renewal,
i.e. the rate of proliferation is too low for e¡ective muscle
repair. Further studies are in progress to investigate the sig-
nalling pathways involved in muscle mass maintenance and
repair.
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